secwatch.observer — SEC 8-K summary
======================================

Issuer:     Kiniksa Pharmaceuticals International, plc (KNSA)
CIK:        0001730430
Form:       8-K
Filed at:   2024-04-23T23:59:59+00:00
Accession:  0001104659-24-050335
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Kiniksa Q1 ARCALYST revenue $78.9M (+85% YoY); raises 2024 guidance to $370-390M
--------------------------------------------------------------------------------

- ARCALYST net product revenue $78.9M in Q1 2024, up 85% YoY; total revenue $79.9M vs $48.3M in Q1 2023.
- Net loss $17.7M vs $12.3M loss in Q1 2023; cash and investments $213.6M, no debt outstanding.
- Raises 2024 ARCALYST net product revenue guidance to $370-390M from prior $360-380M.
- Plans to initiate abiprubart Phase 2b trial in Sjögren's Disease in second half of 2024.
- About 2,000 prescribers have written ARCALYST since launch; average therapy duration ~23 months.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1730430/000110465924050335/0001104659-24-050335-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1730430/000110465924050335/tm2412282d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-24-050335

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer